Investment Overview

Overview

This section covers investment opportunities, funding trends, and market analysis in the neurodegenerative disease space. Understanding the investment landscape helps identify promising therapeutic approaches and company opportunities.

Market Overview

The neurodegenerative disease therapeutic market represents significant unmet need and commercial opportunity: [@alzheimers2024]

• Alzheimer's disease therapeutics: $7B+ annually for disease-modifying therapies (Leqembi, Kisunla driving growth)
• Parkinson's disease therapeutics: $3B+ annually
• ALS therapeutics: $1B+ annually
• Total neurodegeneration market: Projected to reach $65B+ by 2032

Major Pharmaceutical Companies

Alzheimer's Disease

• [Biogen/Eisai](/companies/biogen) — Leqembi (lecanemab) approved 2023, Aduhelm (withdrawn)
• [Eli Lilly](/companies/eli-lilly) — [Donanemab](/entities/donanemab) (Kisunla) approved 2024
• [Roche/Genentech](/companies/roche) — Gantenerumab (failed), Crenezumab (failed)
• [AbbVie](/companies/abbvie) — ACI-35 liposomal vaccine in Phase II

Parkinson's Disease

• [AbbVie](/companies/abbvie) — Duodopa/Duopa (levodopa-carbidopa intestinal gel)
• [Novartis](/companies/novartis) — Ongentys (opicapone), Stalesto (opicapone combo)
• [UCB](/companies/ucb) — Neupro (rotigotine patch)
• [Denali Therapeutics](/companies/denali-therapeutics) — DNL151 (LRRK2 inhibitor)
• [AbbVie partnership](/companies/abbvie) — AAV-delivered gene therapies

ALS

...

Overview

This section covers investment opportunities, funding trends, and market analysis in the neurodegenerative disease space. Understanding the investment landscape helps identify promising therapeutic approaches and company opportunities.

Market Overview

The neurodegenerative disease therapeutic market represents significant unmet need and commercial opportunity: [@alzheimers2024]

• Alzheimer's disease therapeutics: $7B+ annually for disease-modifying therapies (Leqembi, Kisunla driving growth)
• Parkinson's disease therapeutics: $3B+ annually
• ALS therapeutics: $1B+ annually
• Total neurodegeneration market: Projected to reach $65B+ by 2032

Major Pharmaceutical Companies

Alzheimer's Disease

• [Biogen/Eisai](/companies/biogen) — Leqembi (lecanemab) approved 2023, Aduhelm (withdrawn)
• [Eli Lilly](/companies/eli-lilly) — [Donanemab](/entities/donanemab) (Kisunla) approved 2024
• [Roche/Genentech](/companies/roche) — Gantenerumab (failed), Crenezumab (failed)
• [AbbVie](/companies/abbvie) — ACI-35 liposomal vaccine in Phase II

Parkinson's Disease

• [AbbVie](/companies/abbvie) — Duodopa/Duopa (levodopa-carbidopa intestinal gel)
• [Novartis](/companies/novartis) — Ongentys (opicapone), Stalesto (opicapone combo)
• [UCB](/companies/ucb) — Neupro (rotigotine patch)
• [Denali Therapeutics](/companies/denali-therapeutics) — DNL151 (LRRK2 inhibitor)
• [AbbVie partnership](/companies/abbvie) — AAV-delivered gene therapies

ALS

• [Amylyx Pharmaceuticals](/companies/amylyx) — AMX0035 (AMIAS) approved 2022, voluntarily withdrawn 2024
• [Cytokinetics](/companies/cytokinetics) — Reldesomatide (relebNS1303) in Phase III
• [BrainStorm Cell Therapeutics](/companies/brainstorm) — NurOwn (MSC-NTF cells) - Phase 3 completed
• [Clene Nanomedicine](/companies/clene) — CNM-Au8 (nanocatalytic gold) - Phase 2/3 ongoing
• [渤健/Biogen](/companies/biogen) — Tofersen (Qalsody) approved 2023 for SOD1-ALS

Frontotemporal Dementia

• [Alector](/companies/alector) — AL001, AL101 (progranulin enhancers)
• [Denali](/companies/denali-therapeutics) — [TREM2](/proteins/trem2) programs

Investment Trends

Funding Landscape

• Venture capital: $4B+ invested in neurodegeneration in 2025-2026
• Public offerings: Multiple biotech IPOs targeting neurodegeneration
• M&A activity: Large pharma acquiring promising biotechs (Novartis-Versanis Bio $1.9B in 2023, AbbVie-Cerevel $8.7B in 2024, continued M&A in 2025)

Pipeline Focus Areas

• Amyloid-targeting: Monoclonal antibodies, vaccines
• [Tau](/proteins/tau)-targeting: Antibodies, small molecules, aggregation inhibitors
• [Alpha-synuclein](/proteins/alpha-synuclein): Antibodies, aggregation inhibitors, ASO therapies
• Genetic therapies: ASO, RNAi, AAV gene therapy

Clinical Trial Investment

| Phase | Cost per Trial | Success Rate | Time |
|-------|----------------|--------------|------|
| Phase I | $15-30M | 70% | 1-2 years |
| Phase II | $30-60M | 33% | 2-3 years |
| Phase III | $100-200M | 25% | 2-4 years |

Market Projections

Alzheimer's Disease

• Disease-modifying therapies: $10B+ peak sales potential for first successful class
• Early detection: Enabling preventive treatment market
• Diagnostic market: $1B+ for biomarker testing

Parkinson's Disease

• Levodopa delivery: Extended-release formulations drive growth
• Disease-modifying: $3B+ potential market
• Cell therapy: Emerging regenerative approach

Rare Neurodegeneration

• Orphan drug pricing: $500K-$2M per patient annually
• Premium pricing: Limited competition in rare diseases
• Accelerated approval: Faster market access via FDA programs

Investment Risk Factors

Clinical Risk

• High failure rate in Phase III (>70% failure for AD)
• Regulatory uncertainty (Aduhelm approval/reimbursement saga)
• Competition for trial enrollment

Commercial Risk

• Pricing and reimbursement challenges
• Competition from generic symptomatic treatments
• Patient access limitations

Technical Risk

• Target validation uncertainty
• Biomarker development needs
• Manufacturing complexity (biologics, cell therapy)

Deal Flow and Partnerships

Major Recent Deals

• AbbVie + Alector: $750M+ for AL001/AL101
• Biogen + Ionis: $1B+ for ASO programs
• Roche + AC Immune: $500M+ for tau vaccine

Investment Themes

Genetic discoveries → Precision medicine approaches

Biomarker development → Patient selection, monitoring

Blood-based diagnostics → Population screening

Combination therapies → Multi-target approaches

Resources

• [Investment Rankings](/investment/rankings) — companies by investment
• [Market Analysis](/investment/topics/market-landscape) — detailed market data
• [Funding Trends](/investment/topics/investment-trends) — historical analysis

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Topics

• [Investment Overview](/investment/overview) — This page
• [Investment Rankings](/investment/rankings) — Ranked list by research activity
• [Investment Dashboard](/investment/dashboard) — Data visualizations and metrics

Summary Statistics

• [Total Pages:** 97 Investment pages in this section](/investment)
• [Last Updated:** This section is actively maintained](/genes/th)

A-Z All Pages

• [4R Tauopathy Therapeutics — Investment Landscape Analysis](/investment/4r-tauopathy-therapeutics)
• [AAV Gene Therapy for Neurodegeneration — Investment Landscape](/investment/aav-gene-therapy)
• [ALS vs FTD: Comparative Investment Analysis](/investment/als-vs-ftd-comparison)
• [AMPK Activators for Neurodegeneration — Investment Analysis](/investment/ampk-activators)
• [Adaptive Immunity in Neurodegeneration: Investment Landscape](/investment/adaptive-immunity-neurodegeneration)
• [Adenosine A2A Receptor Antagonists: Investment Landscape Analysis](/investment/adenosine-a2a-receptor-antagonists)
• [Adult Neurogenesis Therapeutics Investment Landscape](/investment/adult-neurogenesis-therapeutics)
• [Adult Neurogenesis Therapeutics: Investment Landscape](/investment/adult-neurogenesis)
• [Alpha-Synuclein Therapeutics: Investment Landscape Analysis](/investment/alpha-synuclein)
• [Alzheimer's Disease Investment Landscape](/investment/alzheimers)
• [Alzheimer's vs Parkinson's: Comparative Investment Analysis](/investment/ad-vs-pd-comparison)
• [Ambroxol for Neurodegeneration — Investment Landscape Analysis](/investment/ambroxol-neurodegeneration)
• [Amyloid Therapeutics: Investment Landscape Analysis](/investment/amyloid-therapeutics)
• [Amyotrophic Lateral Sclerosis (ALS) Investment Landscape](/investment/als)
• [Anti-Tau Therapeutics: Investment Landscape Analysis](/investment/anti-tau-therapeutics)
• [Antibody Therapeutics Investment Landscape for Neurodegeneration](/investment/antibody-therapeutics-neurodegeneration)
• [Apoptosis Inhibitors for Neurodegeneration — Investment Landscape Analysis](/investment/apoptosis-therapeutics)
• [Astrocyte Therapeutics for Neurodegeneration: Investment Analysis](/investment/astrocyte-therapeutics-neurodegeneration)
• [Autophagy and Mitophagy Therapeutics Investment Landscape](/investment/autophagy-mitophagy-therapeutics)
• [BDNF Therapy for Neurodegeneration — Investment Landscape Analysis](/investment/bdnf-therapy)
• [Biomarker Investment Landscape](/investment/biomarkers)
• [Blood-Brain Barrier Penetration Technologies Investment Landscape](/investment/bbb-penetration-technologies)
• [Brain-Computer Interface Investment Landscape](/investment/brain-computer-interface)
• [C9orf72 Therapeutics Investment Landscape](/investment/c9orf72-therapeutics)
• [Calcium Signaling — Investment Landscape Analysis](/investment/calcium-signaling)
• [Complement System Therapeutics for Neurodegeneration](/investment/complement-system-therapeutics-neurodegeneration)
• [Corticobasal Degeneration (CBD) Investment Landscape](/investment/corticobasal_degeneration)
• [Corticobasal Degeneration Investment Landscape](/investment/cbd)
• [DNA Damage Repair Investment Landscape](/investment/dna-damage-repair)
• [Deep Brain Stimulation — Investment Landscape Analysis](/investment/deep-brain-stimulation)

[See all 97 investment pages...](/investment/rankings)

References

Biopharma Intelligence, Neurodegeneration Pipeline Analysis (2024)

Alzheimer's Association, Alzheimer's Disease Facts and Figures (2024)

BIO Industry Analysis, Clinical Development Success Rates (2024)